“…In addition, the complete removal of the metal catalyst cannot always be guaranteed, which leads to concerns if the polymers are to be used for biomedical applications. An alternative route involves the use of so‐called organocatalysts, of which the first, 4‐dimethylaminopyridine (DMAP), was introduced in 2001 by Nederberg et al 29 Since then, a wide variety of classes of organocatalysts, such as N ‐heterocyclic carbenes (NHCs), acid catalysts like diphenyl phosphate (DPP), bifunctional thiourea‐amine systems, as well as guanidines and amidines, have emerged 30–35 . While NHCs represent the most extensively studied family of organocatalysts, the guanidine and amidine superbases such as 1,5,7‐triazabicyclo[4.4.0]dec‐5‐ene (TBD), 7‐methyl‐1,5,7‐triazabicyclo[4.4.0]dec‐5‐ene (MTBD), and 1,8‐diazabicyclo[5.4.0]undec‐7‐ene (DBU) have also been of considerable interest.…”